Urasiński I, Zdziarska B, Wichert K, Zuk E
Kliniki Hematologii Instytutu Chorób Wewnetrznych Pomorskiej Akademii Medycznej w Szczecinie.
Pol Merkur Lekarski. 1998 Mar;4(21):137-9.
The treatment of highly of 43 patients with highly malignant non-Hodgkin lymphomas were analysed and assessed. These patients were treated at the Department of Hematology, Pomeranian Medical Academy within 1981-1990. The process was advanced in 76% of and localization of the tumour outside lymph nodes was also seen in 79%. The results of treatment with CHOP regimen used during the first 5 years were compared with CBVPM-AVBP used in 1986-1990. CBVPM-AVBP regimen proved more 4 effective (55% of the complete remissions) than CHOP regimen (37.5% of the complete remission). Mean duration of the complete remission (survival free from the relapse) was 27.5 (1-88) months. Complete remissions were easier to achieve in patients with centroblastic lymphoma in higher percentage. These patients survived longer than those with other highly malignant lymphomas. The authors conclude that further intensification of chemotherapy in case of highly malignant non-Hodgkin lymphomas is justified.
对43例高度恶性非霍奇金淋巴瘤患者的治疗进行了分析和评估。这些患者于1981年至1990年在波美拉尼亚医学院血液科接受治疗。76%的患者病情处于进展期,79%的患者肿瘤位于淋巴结外。将前5年使用CHOP方案的治疗结果与1986年至1990年使用的CBVPM-AVBP方案进行了比较。CBVPM-AVBP方案被证明比CHOP方案更有效(完全缓解率为55%,而CHOP方案为37.5%)。完全缓解的平均持续时间(无复发存活时间)为27.5(1 - 88)个月。中心母细胞性淋巴瘤患者更容易达到更高比例的完全缓解。这些患者的存活时间比其他高度恶性淋巴瘤患者更长。作者得出结论,对于高度恶性非霍奇金淋巴瘤,进一步强化化疗是合理的。